Benzinga | Feb 22, 2021 07:58AM EST

Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral, Announces $162 Price Target

Guggenheim analyst Etzer Darout downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Neutral and announces $162 price target.